Zejula and Keytruda in triple negative breast cancer – pro
The information on this combination is preliminary study of 54 patients presented in May 2019. Preliminary activity is encouraging with durable responses observed irrespective of BRCA1/2 or PD-L1 status or prior platinum exposure with the highest ORR in BRCAmut pts. No new safety signals were identified with the combination. It requires more study.
Shaveta Vinayak, Sara M. Tolaney, Lee Steven Schwartzberg, Monica M. Mita, Georgia Anne-Lee McCann, Antoinette R. Tan, Andrea Elisabeth Wahner Hendrickson, Andres Forero-Torres, Carey K. Anders, Gerburg M. Wulf, Patrick M Dillon, Filipa Lynce, Corrine Zarwan, John Kalil Erban, Bruce Jeffrey Dezube, Yinghui Zhou, Nathan Buerstatte, Sujata Arora, Haroun Achour, and Melinda L. Telli, TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 tial.
Journal of Clinical Oncology 2018 36:15_suppl, 1011-1011
Vinayak S, Tolaney SM, Schwartzberg LS, et al. TOPACIO/Keynote-162: niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018;36(suppl; abstr 1011).
Mirza MR, Monk BJ, Herrstedt J, et al; for the ENGOT-OVl6/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.
NCCN, Breast Cancer 2019